GlaxoSmithKline/ Oxford BioTherapeutics Announce Alliance For Anti-Cancer Antibodies
This article was originally published in The Pink Sheet Daily
Executive Summary
Alliance is first OBT partnership with a big pharma; deal grants biotech double-digit royalties on products it develops through proof of concept.
You may also be interested in...
Oxford BioTherapeutics To Collaborate With Seattle Genetics On ADCs
In tandem with Seattle Genetics, Oxford BioTherapeutics hopes to take a monoclonal antibody product for cancer into the clinic next year.
Oxford BioTherapeutics To Collaborate With Seattle Genetics On ADCs
In tandem with Seattle Genetics, Oxford BioTherapeutics hopes to take a monoclonal antibody product for cancer into the clinic next year.
Deals Of The Week: Shionogi-Sciele/Victory; GSK/OBT; Novartis/Elixir
Each week, "The Pink Sheet" presents commentary on some of the week's most interesting business deals, contributed by the editors of the IN VIVO blog. Visit the blog at 1http://invivoblog.blogspot.com/.